Metabolic Dysfunction-Associated Steatotic Liver Disease

A new model has projected a substantial rise in the burden of metabolic dysfunction-associated steatotic liver disease in the U.S. by 2050, which could be minimized by effective preventive and management strategies, researchers wrote.

New guidance on GLP-1 receptor agonist use, how to tackle medication shortages and expanded continuous glucose monitoring use for type 2 diabetes are among the updates in the American Diabetes Association’s 2025 Standards of Care.

SAN DIEGO — VK2809 demonstrated “robust reductions” in liver fat as early as 12 weeks in metabolic dysfunction-associated steatohepatitis, as well as MASH resolution and improvement in fibrosis by week 52, according to late-breaking data.

SAN DIEGO — Treatment with glucagon-like peptide-1 receptor agonists significantly reduced alanine aminotransferase among children with metabolic dysfunction-associated steatotic liver disease, especially those with type 2 diabetes.

SAN DIEGO — Patients with diabetes who were prescribed glucagon-like peptide-1 receptor agonists had lower odds of metabolic dysfunction-associated steatotic liver disease after liver transplantation, noted a presenter at The Liver Meeting.

SAN DIEGO — Patients treated with once-monthly efimosfermin 300 mg achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis at 24 weeks, according to late-breaking data.

SAN DIEGO — Patients with decompensated alcohol-associated cirrhosis and ascites taking naltrexone had lower risk for all-cause mortality and liver disease complications, including acute kidney injury and spontaneous bacterial peritonitis.

Children with obesity have increased risk for type 2 diabetes if they are diagnosed with metabolic dysfunction-associated steatotic liver disease, according to findings published in Diabetes Care.

SAN DIEGO — Liver stiffness measurements may help predict the risk for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease, as well as identify those in need of surveillance, according to data.

Changes in MRI-derived markers of iron-corrected T1 mapping and liver fat content appear effective at predicting histological response among patients treated for metabolic dysfunction-associated steatohepatitis, according to researchers.